Equities Analysts Offer Predictions for VYGR FY2026 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Voyager Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($1.40) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The business had revenue of $6.47 million for the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

Several other research analysts also recently weighed in on VYGR. Canaccord Genuity Group reduced their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Finally, Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $13.39.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $3.46 on Tuesday. The company has a market cap of $191.46 million, a price-to-earnings ratio of 4.87 and a beta of 0.82. The stock has a 50 day simple moving average of $3.23 and a 200-day simple moving average of $4.42. Voyager Therapeutics has a 1-year low of $2.65 and a 1-year high of $9.55.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently modified their holdings of VYGR. Cubist Systematic Strategies LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC raised its position in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management raised its position in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after acquiring an additional 2,444 shares in the last quarter. CWM LLC raised its position in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after acquiring an additional 9,376 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new position in Voyager Therapeutics in the fourth quarter worth $60,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.